EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework

Yoo Seung-Lai iD

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2561020 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Yoo Seung-Lai. Beteiligte Einrichtung: Department of Pharmacy, Dongduk Women's University, Seoul, South Korea. Hauptthemen laut MEDLINE: Reimbursement Mechanisms, Single-Payer System, Health Services Accessibility. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Timely access to innovative medicines remains a policy challenge in single-payer systems. South Korea has introduced mechanisms such as economic evaluation exemptions and risk-sharing agreements (RSAs) to improve access while maintaining expenditure controls. However, empirical evidence on their real-world impact remains limited. RESEARCH DESIGN AND METHODS: A retrospective observational analysis was conducted using data on 85 new drugs assessed by the Health Insurance Review and Assessment Service (HIRA) between 2022 and 2024. Publicly available HTA datasets were categorized by evaluation outcome, pricing ratios, and projected budget impact. Statistical analyses included descriptive analysis, correlation testing, and multivariable linear regression. RESULTS: Eighty-two percent of assessed drugs were reimbursed. A full recommendation from HIRA strongly predicted listing outcomes. Drugs with moderate budget impact (1.5-10 billion Korean Won) experienced shorter timelines. International price ratios - averaging 64% of the mean level across reference countries - were the only consistent predictors across settings. CONCLUSION: Evaluation outcomes, assessment complexity, and budget forecasts are key determinants of reimbursement in Korea. Refinement of HTA processes and adaptive use of RSAs may enhance access efficiency while preserving budgetary sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reimbursement MechanismsSingle-Payer SystemHealth Services AccessibilityRepublic of KoreaHumansRetrospective StudiesTime FactorsBudgetsPharmaceutical PreparationsDrug CostsTechnology Assessment, BiomedicalRisk Sharing, FinancialPolicy MakingHealth PolicyLinear ModelsInsurance, Health, Reimbursement

Stichwörter der Autor:innen

ReimbursementSouth Koreaeconomic evaluationhealth technology assessmentpharmaceutical policyrisk-sharing agreementssingle-payer system

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Department of Pharmacy, Dongduk Women's University, Seoul, South Korea.

ORCID-Profile: Yoo Seung-Lai

Zitieren

APA

Seung-Lai, Y. (2025). Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2561020

Vancouver

Seung-Lai Y. Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2561020

BibTeX
@article{SeungLai2025,
  author = {Seung-Lai, Yoo},
  title = {Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2561020}
}
Kostenlos starten →